Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Swapping one GLP-1 for another isn't as simple as changing a prescription. Primary care providers need to account for long half-lives, prior dose history, and glycemic risk when transitioning patients. Experts say no washout period is needed — just start the new agent when the next dose of the old one would have been due, and titrate carefully from there.
As GLP-1 receptor agonists and dual incretin agents become go-to treatments for obesity and type 2 diabetes, primary care providers are increasingly navigating medication switches — whether driven by insurance coverage, side effects, or inadequate response. The good news: because these drugs have long half-lives, no washout period is needed. Experts recommend starting the new agent exactly when the next dose of the prior one would have been due, avoiding both treatment gaps and therapy overlap.
But the switch isn't one-size-fits-all. Titration should be individualized based on how well a patient tolerated the previous agent — those who breezed through the first titration can often escalate faster, while others need a slower approach. If a patient has been off their GLP-1 for more than 2–3 weeks, re-titration from a lower dose is essential to avoid GI intolerance.
Key Takeaways:
Why it matters: With GLP-1 prescriptions surging, poorly managed switches can lead to hypoglycemia, GI side effects, or patients abandoning effective therapy altogether. A deliberate, individualized approach keeps patients safe and on track.
